The Taiwan biotech industry maintained significant profitability in 2025, with at least 10 companies earning more than one share capital and over 20 firms reporting an EPS exceeding NT$5. While foreign exchange fluctuations and a cooling global economy slightly tempered growth compared to 2024, the sector’s operational core remains resilient.
Read more
